GRL0617

• Description :

  GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome[1].

• Product Name Alternative :

  8-Nitrotryptanthrin

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Deubiquitinase; SARS-CoV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Cell Cycle/DNA Damage

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/grl-0617.html

• Concentration :

  10mM

• Purity :

  99.62

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  O=C(N[C@@H](C1=C2C=CC=CC2=CC=C1)C)C3=CC(N)=CC=C3C

• Molecular Formula :

  C20H20N2O

• Molecular Weight :

  304.39

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ratia K, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008 Oct 21;105 (42) :16119-24.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1093070-16-6]